We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

After the Centers for Medicare & Medicaid Services announced the selection of 15 additional drugs covered under Medicare Part D for price ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Spain — one of Europe's fastest growing economies, according to the OECD — is set to publish import and export figures on ...

Linden Thomson, senior fund manager at Candriam, notes that weight-loss drugs have become the driver of healthcare investing. “The obesity opportunity is one that people can really understand and has ...

After the Centers for Medicare & Medicaid Services announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations – including Novo Nordisk’s (NVO ...

Novo Nordisk shares have pared some losses but ... over the company's blockbuster weight loss and diabetes drugs. JPMorgan analysts said they had previously forecast a 50% cut in prices for ...